MTMichael Tilghman Treadway

Michael Tilghman Treadway

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Michael Tilghman Treadway has a total of 187 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Did I do that? Efficacy estimation distinguishes rumination and anhedonia symptomatology

    by Marta Migó, Vanessa M. Brown, Jessica A. Cooper, Jonathan Ryan, Peter F. Hitchcock, Michael T. Treadway

  • Open Access

    Motivational and Consummatory Anhedonia Represent Distinct Affective and Behavioral Responses to Effortful and Rewarding Activities in Daily Life

    by Tatiana Pillsbury, Samantha A. Betters, Marta Migo, Shiyin Liu, Aje Oluwagbohunmi, Sarah Etuk, Wenwu Sun, Caroline Conway, Michael Tilghman Treadway, Jessica Cooper

    Anhedonia is a common psychiatric symptom defined as a loss of interest in or ability to enjoy previously rewarding activities. Although early definitions of anhedonia conceptualized it as a unitary construct, more recent formulations have emphasized the potential importance of distinguishing changes in motivation (motivational anhedonia; “MA”) from changes in hedonic capacity (consummatory anhedonia; “CA”). Evidence for these two domains has been derived from animal models highlighting distinct neurobiological pathways supporting motivational and hedonic responses, as well as human behavioral and pharmacological work highlighting distinct effects of these pathways on motivated and consummatory behavior. While this foundational work has been broadly supportive of the distinction between MA and CA, it remains unknown whether these two domains produce clinically meaningful differences in lived experience of daily activities. In the current work, we used an experience sampling approach in 162 adults (48.7% with current anhedonia as determined by clinical interview) to determine whether self-reported differences in MA and CA severity would be differentially associated with effort and reward levels of activities planned and completed in daily life. Consistent with the hypothesis that MA and CA are meaningful constructs, we observed markedly different associations with behavior in daily life. While elevated MA was associated with effort aversion, higher CA was associated with selective deficits in selecting rewarding activities. Moreover, symptoms of MA and CA were associated with distinct patterns of affective responses to levels of effort and reward in experienced activities. These data provide evidence for distinct manifestations of MA and CA in daily life and further support the hypothesis that they reflect distinct etiopathophysiologies that may benefit from different treatment strategies.

  • Nociceptin orphanin F/Q Pathways are dysregulated by stress and modulate reward responsiveness and motivated behavior across species

    by Diego A. Pizzagalli, Meghan Gallo, Michael T. Treadway, Brian D. Kangas, Jocelyn Breton, Michael R. Bruchas, Ann M. Graybiel, Emily Hueske, Kevin G. Bath

    Nociceptin orphanin F/Q has been implicated in stress-related depressive phenotypes. Specifically, exposure to chronic stressors upregulates nociceptin receptors (NOPR), whereas NOPR antagonism has antidepressant/anti-anhedonic effects. However, the mechanisms underlying reward-related effects remain unclear. Here, we investigated the role of NOPR in a broad spectrum of reward-related phenotypes (reward consumption, reward learning, motivated behavior) alongside potentially prohedonic effects of NOPR antagonism across species. Study 1 evaluated whether exposure to early-life adversity upregulated ventral tegmental area (VTA) and striatal prepronociceptin (Pnoc) gene expression in adult mice. Study 2 assessed whether NOPR antagonism boosted reward learning in rats using the touchscreen-based Probabilistic Reward Task. Finally, Study 3 tested whether NOPR antagonism modulated decision about motivated behavior using the Effort Expenditure for Reward Task among depressed humans. In Study 1, early-life adversity induced reduced sucrose preference and produced enduring and sex-dependent alterations in effort-related reward behavior, and increased Pnoc expression in the VTA; in females (but not males), early-life adversity increased Pnoc expression in the dorsal striatum. In Study 2, acute administration of 30 mg/kg (but not lower doses) of a NOPR antagonist (BTRX-246040) enhanced reward learning in rats. Finally, in Study 3, relative to placebo, 8-week treatment with BTRX-246040 modulated choice consistency during a motivated task in depressed humans. Collectively, our findings indicate that chronic stress alters Pnoc and mRNA levels of Pnoc-expressing cells in a sex-selective and region-specific manner impacting reward structures, and that NOPR antagonism shows promising efficacy in increasing reward-related behaviors in rodents and humans. Future studies using similar manipulations and outcome measures across species are warranted.

  • Open Access

    Ventral striatum temporal interference brain stimulation enhances the reward-positivity event-related potential and reduces anxiety

    by Jonathan S. Ryan, Timothy J. McDermott, Boris Botzanowski, Jessica R. Kubert, Samantha Betters, Aje Oluwagbohunmi, Summer B. Frandsen, Travis M. Fulton, Adam Williamson, Michael T. Treadway, et al.


  • Computational phenotypes underlying effort-based decision-making and negative symptoms in a transdiagnostic severe mental illness sample

    by Lauren Luther, Jessica A. Cooper, Michael T. Treadway, Anna R. Knippenberg, Elaine F. Walker, James M. Gold, James A. Waltz, Jason Schiffman, Lauren M. Ellman, Vijay A. Mittal, et al.

    Effort-based decision-making (EBDM) impairments predict negative symptoms across multiple psychiatric diagnoses. However, it is unclear whether equifinality is present and different disorders reach the same clinical endpoint of negative symptoms via different mechanistic EBDM processes. This study used computational modeling to isolate processes underlying EBDM in a large severe mental illness-spectrum sample. The Effort Expenditure for Rewards Task, negative symptom measures, and neuropsychological tests were administered to 920 participants: schizophrenia (SZ; n = 147), first-episode psychosis (FEP; n = 54), bipolar disorder (n = 53), depressive disorder (n = 37), clinical high-risk for psychosis (CHR; n = 231), other clinical (n = 99), and healthy control groups (HC; n = 299). Computational modeling identified whether participants' EBDM behavior was best fit by models indexing full or partial subjective value (use reward magnitude and/or probability) or bias (failure to use reward magnitude and probability). Best fitting models significantly differed across diagnostic groups. SZ and FEP were best fit by the bias model and less likely to use reward magnitude and probability to guide EBDM. The CHR, other clinical, depressive disorder, and HC groups were best fit by the full subjective value model and were more likely to use reward magnitude and probability, while the bipolar disorder group’s behavior was more variable. Across groups, participants best fit by the bias model had the greatest negative symptoms and cognitive impairments. Results indicate mood and psychosis-spectrum disorders differentially approach EBDM. Equifinality in the pathway to negative symptoms was not supported; those with difficulty utilizing reward and probability information had the greatest negative symptoms, independent of diagnosis.


  • Open Access

    What's the goal? Reconsidering the importance of higher-order cognition in internalizing psychopathology

    by Marta Migó, Michael Tilghman Treadway

    To date, the field of computational psychiatry has largely focused on testing for dysfunction within lower-level cognitive processes in psychopathology, such as biases related to attention, reinforcement learning and memory. While this work has yielded important insights, there is clear evidence from empirically validated psychotherapeutic interventions to suggest that these lower-level cognitive processes are often intact. Here, we argue that etiological and maintaining factors for internalizing disorders may be more appropriately situated in higher level cognitive processes such as goal-selection. We further suggest that future research should incorporate behavioral tasks and models that allow for participant-defined goals to reveal higher-level mechanistic targets. We believe that these higher-level deficits in goal-selection, possibly in tandem with low-level impairments, may augment ecological validity and clinical relevance.

  • Open Access

    Obesity, low-grade inflammation, and inflammatory response to immune challenge modulate willingness to expend effort for reward

    by Iris Ka-Yi Chat, Lina Hansson, Mats Lekander, Charlotta Jacobsen, Sven Benson, Johannes Hebebrand, Vera Bender, Analena Handke, Till Hasenberg, Michael Tilghman Treadway, et al.

    Background: Inflammation is increasingly considered a vulnerability factor for deficits in reward motivation. It remains unclear if such motivational changes differ between acute and chronic low-grade inflammation. Given obesity’s link to chronic low-grade inflammation, the present study tested the effect of obesity and the impact of low-grade inflammation (elevated CRP concentrations), as well as the effect of acute inflammation (experimental immune challenge using lipopolysaccharide), on motivation for a monetary reward. Moreover, the wear-and-tear induced by chronic inflammation could amplify motivational changes induced by immune challenge. Thus, we also tested the hypotheses that acute inflammation is associated with more strongly altered reward motivation for individuals with higher low-grade inflammation, and for obese than normal-weight individuals.Methods: Healthy obese (n=14) and normal-weight (n=21) young adults were intravenously injected with a bacterial endotoxin (lipopolysaccharide, LPS [0.8 ng/kg body weight]) to trigger an acute inflammatory response, and placebo (saline) in a counterbalanced, randomized, crossover design. The Effort Expenditure for Reward Task (EEfRT) was administered 2 hours following each injection to assess reward motivation. Blood was sampled pre- and post-injection to quantify concentrations of inflammatory proteins (interleukin [IL]-6 and C-reactive protein [CRP]).Results: Obese participants and higher low-grade inflammation (baseline CRP) was associated with overall reduced motivation to expend effort for reward in the placebo condition. An interaction with reward magnitude was observed, so that this effect occurred at smaller reward values, but not when reward values increased. LPS-induced inflammatory responses (IL-6 concentrations during EEfRT) were associated with a weaker influence of reward magnitude on increasing effort. Unexpectedly, we did not detect the amplification effect of obesity and its associated low-grade inflammation on the ability of lipopolysaccharide to modulate reward motivation.Conclusions: Lipopolysaccharide-induced and low-grade inflammation alter how effort is allocated towards reward, with low-grade inflammation increasing the reward threshold for exerting effort and acute inflammation dampening reward sensitivity. This study offers a nuanced understanding of inflammatory processes underlying alterations in reward motivation.


  • Inflammation is associated with avolition and reduced resting state functional connectivity in corticostriatal reward circuitry in patients with schizophrenia

    by David R. Goldsmith, Courtney S. Ning, Gregory P. Strauss, Robin E. Gross, Jessica A. Cooper, Evanthia C. Wommack, Ebrahim Haroon, Jennifer C. Felger, Elaine F. Walker, Michael T. Treadway, et al.

    Low-grade inflammation has been associated with negative symptoms in patients with schizophrenia. Of these symptoms, deficits in motivation and pleasure, especially in the domain of avolition, are particularly disabling. Effects of inflammation on motivational deficits in patients with depression are associated with disruptions in corticostriatal reward circuitry involving the inferior ventral striatum (iVS) and ventromedial prefrontal cortex (vmPFC). Accordingly, we examined the relationships among inflammation, negative symptoms, and corticostriatal reward circuitry in patients with schizophrenia. Negative symptoms and high sensitivity C-reactive protein (hsCRP) were obtained in 57 individuals with schizophrenia. Resting state functional connectivity (rsFC) was obtained from a subset of 43 of these individuals. Associations were tested between hsCRP and the motivation and pleasure (MAP) and expressivity (EXP) dimensions of the Brief Negative Symptom Scale (BNSS) as well as targeted rsFC between iVS and vmPFC. Covariates in all statistical models included age, sex, race, smoking, body mass index, depression, and chlorpromazine equivalents. hsCRP was significantly associated with BNSS MAP (β = 0.34, pcorr = 0.022, specifically the domains of avolition and asociality (p < 0.05), but not BNSS EXP (β = −0.17, pcorr = 0.57) or the domains of blunted affect or alogia (both p > 0.05). hsCRP was also significantly associated with decreased rsFC from right iVS to vmPFC (β=−0.37, pcorr = 0.029), which in turn, was associated with increased avolition in individuals with higher (hsCRP >2 mg/L) but not lower inflammation (β=−14.01, p = 0.007 vs. β = 0.07, p = 0.77, respectively). hsCRP was associated with reduced avolition and corticostriatal rsFC in patients with schizophrenia and increased inflammation, underscoring the need for further research to replicate these associations with brain connectivity changes in this subgroup of individuals with schizophrenia.